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Abstract
Background To study the results of the translocation of a free
autologous retinal pigment epithelium (RPE)-choroid graft
after removal of a subfoveal choroidal neovascular mem-
brane in patients with exudative age-related macular degen-
eration (AMD), and to determine whether preoperative
variables may predict visual outcome at 1 year after surgery.
Methods Prospective interventional case series of 84 eyes
of 83 consecutive eligible patients with exudative AMD
with a minimal follow-up of 1 year after surgery. Of this
group, 45, 24 and 11 patients reached a follow-up of
respectively 2, 3 and 4 years. Pre- and postoperative
evaluation included ETDRS visual acuity (VA), fixation
testing and color fundus photography. Preoperative fluores-
cein angiograms were assessed by masked readers for
lesion size, size of hemorrhage and lesion composition
according to the MPS criteria. The relationship between
lesion composition adjusted for preoperative delay and VA,
lesion size, percentage of blood, and visual outcome at
1 year after surgery was analyzed.
Results The mean VA (logMAR) improved slightly at 1 and
2 years (0.89, Δ=−0.06), 3 years (0.79, Δ=−0.16) and
4 years (0.74, Δ=−0.21) after surgery. Five patients had a
preoperative VA better than 20/80, compared to 19 out of 84,
six out of 45, four out of 24 and two out of 11 after 1, 2, 3 and
4 years respectively. Fixation was located on the graft in 62
patients (74%) up to the last examination. Predominantly
classic and occult lesions had a significant better prognosis
than minimally classic or hemorrhagic (≥50% blood) lesions.
Retinal detachment occurred in seven patients; two caused
by rhegmatogenous detachment and five caused by prolifer-
ative vitreoretinopathy. In 11 eyes, a recurrent or persisting
neovascular membrane was observed.
Conclusion An autologous free RPE-choroid graft may
stabilize or improve vision in patients with exudative AMD
up to 4 years after surgery.
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Introduction
In industrialized countries, age-related macular degeneration
(AMD) is the principal cause of irreversible legal blindness in
elderly persons [3, 16, 30]. In the exudative form, the most
promising treatment modality are pharmacological agents.
Recently, anti-VEGF treatment has for the first time showed
visual improvement [10, 13, 31]. Surgical approaches have
also been reported, generally as pilot studies.
Submacular CNV removal was found ineffective in
preserving or regaining useful vision [7, 11, 12, 25]. The
functional restoration achieved in some AMD patients after
macular translocation with a 3600 retinotomy proved the
potential of creating a fresh surface of functioning RPE
cells [8, 27, 28]. A tilted image in successfully operated
patients, complex surgery and numerous complications,
however, remained drawbacks of this technique.
Several strategies have been reported to reconstitute the
submacular RPE after CNV extraction, with transplantation
of sheets of homologous fetal RPE and suspensions of
autologous iris pigment epithelium or RPE cells. However,
there is a lack of demonstrable presence or function of these
transplants in patients [4, 5, 23]. Peyman et al. first reported
the translocation of a free full-thickness autologous graft
consisting of RPE, Bruch’s membrane, choriocapillaris and
choroid taken from the paramacular region in one patient
[29]. This approach was refined in Moorfield’s Eye
Hospital [19, 32]. To minimize trauma to the macular area,
we pioneered a technique to cut out the graft from the
midperiphery [22, 24]. The feasibility of this technique has
recently been confirmed in other pilot studies [15, 20].
The present report concerns the results of the transplan-
tation of a free RPE-choroid graft harvested from the
midperiphery in a larger group of patients up to 4 years after
surgery. We also wished to study whether we could identify
preoperative conditions predictive for visual outcome.
Patients and methods
Patients
We report the data of 84 eyes of 83 consecutive eligible
patients with exudative AMD (one patient had both eyes
treated). Patients were eligible if they had a subfoveal CNV
membrane, with or without submacular blood, not treatable
by other modalities available at that time in our hospital
(laser, photodynamic therapy from May 2003 onwards) and
before the introduction of Avastin (bevacizumab). Exclu-
sion criteria for surgery included a CNV with an etiology
other than AMD (e.g. angioid streaks), a visual acuity (VA)
of >20/80 and a history of symptomatic visual loss for more
than 6 months.
The Institutional Review Board of the Rotterdam Eye
Hospital approved the study; written informed consent was
obtained from all patients in accordance with the ethical
standards laid down in the Declaration of Helsinki. The first
patient was included in October 2001, and the censoring
date was June 2006.
Preoperative examination included best-corrected
ETDRS VA (Snellen and logMAR equivalents), dilated
funduscopy, fluorescein angiography (FA) or indocyanine
green (ICG) angiography. Postoperative visits were sched-
uled at 1, 3 and 6 weeks, at 3, 6, 9, 12, 18 months, as well
as 2, 3 and 4 years. During each visit, best corrected
ETDRS VA testing was performed.
Foveal fixation and retinal sensitivity over the graft were
determined in all patients with biomicroscopy. In addition,
depending on the temporary availability of this device in
our hospital, fundus micro perimetry MP-1 (Nidek, Padova,
Italy) was performed in selected patients to determine
retinal sensitivity and fixation stability over the graft.
Fixation was classified as stable, relatively unstable or
unstable [9].
Every year after surgery, color fundus pictures were
taken. The graft was monitored with optical coherence
tomography (OCT) by 6-mm radial scans (Zeiss stratum
OCT, model 3000, Carl Zeiss, Jena, Germany).
Grading of preoperative images
Masked readers (HH and TM) independently assessed the
preoperative stereo color fundus photographs and FAs.
Pictures were imported into image analysis software
(ImageJ for Mac OC X, National Institute of Health,
Bethesda, MD, USA). The fundus pictures and FA were
used for identification of disc area (DA), lesion size (in DA;
all lesion components taken together) and composition, and
size of hemorrhage (in DA and % of lesion). Lesion
composition (predominantly classic, minimally classic or
occult) was classified with FA according to the Macular
Photocoagulation Study (MPS) [21]. If a lesion was
covered with an extensive hemorrhage (≥50% of the
lesion), the lesion was labeled a “hemorrhagic lesion”.
Surgery
After the induction of a posterior vitreous detachment, a
complete vitrectomy was performed.
The choroidal membrane was removed from the sub-
retinal space with a Thomas subretinal forceps through a
paramacular retinotomy in the temporal raphe (Fig. 1a).
After circular heavy diathermia in the midperiphery at the
12 o’clock position and removal of the retina within the
diathermia marks, vitreous scissors were used to cut a full-
thickness graft of RPE-choroid of approximately 1.5–2.5×
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2–3 mm (Fig. 1b). The graft was loaded onto an aspiration-
reflux spatula (Fig. 1c) (Dutch Ophthalmic Research Center
(DORC), Zuidland, The Netherlands) and repositioned
under the macula through the existing paramacular retinot-
omy (Fig. 1d). Perfluorocarbon liquid (PFCL) was injected
to keep the graft in place and facilitate the release of the
graft when retracting the instrument. The midperipheral
donor site was surrounded with laser coagulation followed
by a silicone oil tamponade. In a second procedure,
approximately 3 months later, the silicone oil was removed.
Lensectomy and insertion of an intraocular lens (IOL) were
performed during the first or second surgery in phakic
patients. One vitreoretinal surgeon (JvM) performed all
surgeries.
Statistical analysis
Analysis of covariance (ANCOVA) was used to analyze the
relation between the four lesion composition groups
(minimally classic, predominantly classic, occult or hemor-
rhagic), adjusted for the following variables: 1) preopera-
tive delay (i.e. time between onset of symptoms and
surgery), 2) preoperative VA, 3) lesion size, and 4)
percentage of blood, and the outcome variable: postopera-
tive VA at 1 year after surgery. The postoperative VA was
reported as logMAR and Snellen equivalents, or less than
two or three ETDRS lines loss.
All analyses were performed using SPSS (Windows
version 12.0; SPSS Inc., Chicago, USA).
Results
Completion of scheduled examinations
Of 92 consecutive AMD patients treated with an RPE-
choroid graft translocation for ≥1 year after initiation of this
study, 83 patients (84 eyes) (91%) completed the 1-year
follow-up. Fifty-seven of these 83 patients had reached the
2-year follow-up. Complete data were available in 45 of
these 57 patients (79%). The 3-year follow-up was
completed in 24 out of 27 patients (89%), and all 11
patients completed the 4-year follow-up.
Reasons for loss of follow-up were: deceased of
unrelated causes (n=7), physically unable to return for the
follow-up (n=8) and loss of contact (n=8).
The visual outcomes of the patients lost during follow-
up are incorporated in the Kaplan–Meier plot (Fig. 3).
Baseline characteristics
The age of the 83 patients (49 females and 34 males) was
79±8 (mean ± SD) years (range 57–95 years). The
preoperative delay in the operated eye (n=84) ranged from
1 week to 6 months (mean of 10 weeks). Patients with a
hemorrhagic lesion (≥50% blood) had a mean delay of
5 weeks after onset of symptoms, compared to 10 to
14 weeks in the other groups.
Forty patients used anticoagulants. They were asked to
discontinue these medications 2 weeks prior to surgery.
Fig. 1 Schematic overview of
the translocation of a free autol-
ogous full-thickness RPE-choroid
graft in patients with exudative
AMD. a Extraction of the
subfoveal neovascular
membrane. b The graft is cut
out and prepared from the
sclera in an area demarcated
with coagulations in the mid-
periphery. c Loading of the
graft on a spatula or grasped
with forceps (not shown in
figure). d Insertion of the graft
in the submacular space while
injecting perfluorocarbon liquid
(PFCL). Medical art work by
Dr. Jessica Leenen
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Twenty-two patients were initially pseudophakic. None of
the patients remained phakic.
Grading of preoperative images
The preoperative FAs together with a fundus image were
available in 68 (out of 84) eyes. FA lacked in 16 patients:
erroneously, in seven patients only an ICG was obtained
because of macular hemorrhages. In eight patients, FAs
were made and evaluated before surgery, but were lost
before evaluation by our masked readers; and in one patient
the FA was made 6 months before surgery and therefore
excluded. The lesions of these 16 eyes were not analyzed.
The two independent masked readers classified the FA
differently in seven eyes, but consensus was reached after
consultation. According to the MPS criteria, nine patients
had a predominantly classic, 14 a minimally classic, 18 an
occult subfoveal neovascularization and 27 were classified
as hemorrhagic lesion (≥50% blood). The size of the total
lesion varied from 1.5 to 72 MPS disk areas (DA)(mean
10 DA). Subretinal blood was present in all but six (out of
68 available) angiograms.
Visual outcome
Mean preoperative VA was 0.95 logMAR (range 1/300 to
20/80), and 0.89 logMAR (range 1/300 to 20/32) after 1
and 2 years, 0.79 logMAR (range 1/60 to 20/25) after
3 years, and 0.74 logMAR (range 20/800 to 20/32) after
4 years. This represents no average change in ETDRS lines.
Five patients had a preoperative vision of 20/80, whereas
19 out of 84 patients had a VA of 20/80 or better after
1 year, and six out of 45, four out of 24 and two out of 11
after 2, 3 and 4 years respectively (Fig. 2).
A loss of ≤2 (<3) ETDRS lines was observed in 76% (64
out of 84) to 82% (9 out of 11) from 1 to 4 years after
surgery respectively (Fig. 3).
The mean VA at 1 year after surgery in the four lesion
composition groups was 1.09 logMAR in the minimally
classic, 0.96 logMAR in the hemorrhagic, 0.82 logMAR in
the predominantly classic and 0.77 logMAR in the occult
lesion group.
If a last observation carried forward method was applied
to these data (n=92) (to correct for patients lost to follow-
up), mean VA was 0.91, 0.93, 0.92 and 0.93 logMAR at 1,
2, 3 and 4 years after surgery respectively.
Foveal fixation on the graft viewed by biomicroscopy
was present in 74% (62 out of 84) of the eyes up to the last
examination. Twelve patients lost their fixation over the
graft during follow-up, associated with a decrease in VA
(mean 1.48 logMAR).
Retinal sensitivity could be demonstrated over the graft
in 16 of 19 patients examined with the NIDEK MP-1
(Fig. 4). Nine of these patients had fixation over the graft;
three of them were graded as stable and six as relatively
unstable. Of the ten eyes without fixation over the graft at
the time of examination with the MP-1 microperimeter, six
eyes gained fixation during follow-up.
Imaging
Postoperative angiograms were performed in 27 patients; in
14 both FA and ICG, in eight FA only and in five ICG only.
Indications for a postoperative angiography were suspicion
of a central retinal vein occlusion (n=1) or recurrent/
persistent CNV (n=17), an unexplained loss of VA (n=2),
Fig. 3 Kaplan–Meier plot of percentage of patients (n=92) who had
<3 (≤2) ETDRS-lines loss. The patients lost within the 4-year follow-
up are included
Fig. 2 Preoperative versus postoperative visual acuity (logMAR).
a–d At 1, 2, 3 and 4 years after surgery (n=84, 45, 24 and 11
respectively). Data points above the diagonal line indicate patients
with visual improvement
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research purposes (n=4) and suspicion of pathology in the
fellow eye (n=3).
Early fluorescence of the graft was seen in 21 of the 22
FAs obtained from 1 month to 4 years after surgery (Fig. 4).
In 10 of 19 ICGs, obtained from 1 to 27 months after
surgery, perfusion of the parallel oriented graft vasculature
could be identified in the early phases of the ICG (Fig. 4).
In seven patients without visualization of the graft
vasculature with ICG, FA showed early fluorescence (in
one patient the FA was not performed). The graft that
lacked fluorescence with early FA also had no signs of
choroidal graft perfusion with ICG.
The graft had a brown, velvety appearance in 60 eyes. In
three patients the graft had a convex shape, in two eyes one
side was folded, in two eyes the graft was small (<1 DA),
and in two patients the graft had become fibrotic. In these
nine patients, VA was ≤20/250 (mean 20/640) after 1 year.
Irregular accumulation of hyperpigmentation at the margins
or near the graft, and sometimes on the graft, could be seen
in 59 patients, starting from 3 months after surgery (mean
7 months) and increasing in time (Fig. 4). Except for this
hyperpigmentation, the position, size and shape of the graft
did not change during follow-up.
OCT of the graft was performed in 55 patients. The graft
RPE layer was observed in all 55 patients up to 4 years
after surgery (Fig. 4). The photoreceptor layer was absent in
14 (25%) patients with a mean VA of 1.05 logMAR, and
present but suboptimal in 41 (75%) with a mean VA of 0.77
logMAR (P=0.012). In 16 (29%) patients, cystic spaces
were present at time of OCT imaging.
Complications during surgery
A complete posterior vitreous detachment (PVD) was
present in only ten patients at the start of surgery; in all
others a PVD had to be induced, with remaining hyaloid (as
a result of hyaloidal schizis) covering the retina in 42
patients.
Complications during surgery occurred in 17% (14 out
of 84) of the patients and consisted of a CNV-membrane
attached to the retina (n=1), a large choroidal defect after
removing the CNV-membrane (n=1), damage to the
papillomacular bundle (n=1), trauma of the subfoveal
choroid with bleeding (n=6, two of which were caused by
manipulation of the graft during repositioning), tearing of
the retinotomy with bleeding (n=2), a peripheral retinal tear
(n=1), a retinal detachment (n=1) and loss of the graft
through the sclerotomies with the need to prepare a second
graft (n=3).
The main problems encountered were failure of the
subfoveal release of the graft (n=18), an inadequate
positioning or incomplete flattening of the graft (n=56),
which was partly folded or wrinkled underneath the fovea.
In 12 of these cases the graft had to be removed and was re-
inserted. To optimize the position or to unfold the graft,
reposition by manipulating the subfoveal graft was per-
formed in these 74 patients (88%).
Postoperative complications
After surgery, a recurrent or persistent CNV membrane was
observed in 11 patients (13%) (range 2 to 27 months after
surgery). Ten CNV membranes were closed by thermal
laser treatment and recently (June 2006) in one patient,
Avastin (bevacizumab) was injected. In these 11 recurren-
ces, vision dropped to counting fingers in seven patients,
three remained stable after treatment (VA of 20/100) and
one patient even improved to a VA of 20/80, with 20/125 at
the last examination 2 years after surgery.
Retinal detachment (RD) occurred in seven patients
(8%); five due to proliferative vitreoretinopathy (PVR) and
two with a rhegmatogenous cause. One rhegmatogenous-
RD developed before silicone oil removal, one rhegmatog-
enous-RD and three PVR-RDs occurred after, and in two
Fig. 4 Imaging of a free RPE-choroid graft. a Fluorescein angiogra-
phy. The graft fluorescence emerges simultaneously with the
surrounding fundus in the early phase. b Indocyanine green
angiography reveals perfusion of the parallel oriented vessels of the
graft. c–d Fundus images with typical accumulations of pigmentation
alongside and on the graft increasing over time. e OCT image. The
retina overlying the graft has a layered structure, foveal depression,
present but suboptimal photoreceptor layer. f Microperimetry shows
function on the graft
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patients PVR-RD occurred both before and after silicone oil
removal. Two of these seven patients had ≥3 lines increase
in vision, one had two lines increase, three remained stable
and one had lost two lines in vision before the development
of RD. Membrane peeling and repeat silicone oil tampo-
nade were performed. Compared to preoperative VA, at the
last examination after RD-repair, six of these seven patients
lost more than three lines and only one had three lines
visual improvement up to the last examination.
In one patient, a local macular RD developed secondary
to a macular pucker before silicon removal. After reattach-
ment, VA improved from 20/800 to 20/125 at the last
examination at 17 months after surgery.
In nine patients, postoperative hemorrhages occurred:
one suprachoroidal bleeding, seven subretinal and one
patient both a subretinal and vitreous hemorrhage. These
hemorrhages were self-limiting, except for two that needed
surgical intervention; a suprachoroidal bleeding and one
caused by a large subfoveal CNV (see above). These
hemorrhages occurred between 1 week and 6 months after
surgery both in patients with (n=6) or without (n=3)
anticoagulant use.
Optic disc atrophy was observed in one patient, and
acute glaucoma in five patients. Two of the latter needed
peripheral iridectomy. A non-ischemic central retinal vein
occlusion occurred in one patient after 8 months. One
patient suffered from a retinal artery occlusion after surgery.
Silicone oil had been removed in all patients, typically 3 to
4 months after the first procedure. When removing the
silicone oil, some degree of retinal puckering/cellophane
maculopathy was present in 90% (76 out of 84) of the patients.
The ILM was removed in these patients using ICG staining.
Predictors for visual outcome
ANCOVA analysis revealed a significant correlation be-
tween the preoperative CNV classification (n=68), adjusted
for preoperative delay, baseline VA, lesion size, and
percentage of blood, and the outcome variable: postopera-
tive VA 1 year after surgery defined as logMAR (P=0.026)
or Snellen equivalents (P=0.014); predominantly classic
and occult lesions had a significant better prognosis than
minimally classic or hemorrhagic (≥50% blood) lesions.
There was no significant difference between the four
lesion composition groups if the outcome was defined as
less than two (P=0.129) or three (P=0.333) ETDRS lines
loss 1 year after surgery.
By analyzing the correlation between all preoperative
variables (except lesion composition) and visual outcome
with ANCOVA, the preoperative VA turned out to be the
strongest (but not statistically significant) prognostic factor.
Also, no significant correlation was found when preoper-
ative delay was assessed as intervals of more or less than 4
and 6 (the latter is the median delay) weeks and postoper-
ative visual outcome (defined as ETDRS-VA or less than
two or three ETDRS lines loss) at 1 year after surgery.
Discussion
A free autologous RPE-choroid graft stabilized the mean
VA up to 4 years after surgery (0.74 logMAR, Δ=−0.21)
after CNV removal in patients with exudative AMD.
Despite the occurrence of serious intra- and postoperative
complications, such as 8% retinal detachments (RD), a VA
of 20/80 or better was observed up in some patients up to
4 years after surgery. Fixation over the graft was achieved
in 74% of the eyes up to the last examination.
This study did not reveal a significant correlation
between preoperative delay, even when analyzed in time-
intervals (delay more or less than 4 or 6 weeks). This is
surprising, as one would assume that the longer the CNV-
membrane would be present beneath the fovea prior to
surgical intervention, the more extensive the photoreceptor
loss and the less beneficial an RPE-choroid graft would be
to visual acuity . We assume that either the number of
patients was too small to detect a correlation, or that other
variables not included (such as intra-operative variables)
acted as confounding factors.
As a predictor for better visual outcome in order to be
more selective in patients to treat, predominantly classical
membranes were identified in this study as the best
candidate, as with photodynamic therapy [34–36]. In the
SST-trial, and in studies on full macular translocation, no
obvious best candidates were found [7, 12, 26].
Our functional results compare favorably with two other
groups recently reporting on graft translocation in AMD
patients, possibly because our RD rate of 8% is low compared
to theirs of 31% and 42% [15, 20]. This difference may be
related to a difference in operating technique, as Joussen et al.
harvested the graft from the inferior midperiphery. Another
possible surgical cause may be our painstaking removal of all
remaining hyaloid (which requires visualization by triamcino-
lon acetonide crystals when working with a chandelier
illumination) to prevent remaining hyaloid forming a scaffold
for epiretinal membranes. Remarkably, a complete posterior
vitreous detachment was rare in these patients.
Our visual results, as well as our rate of RD, also
compare favorably with those obtained by simple mem-
brane extraction alone (RD rate of 5–16%), as demonstrated
by the submacular surgery trial (SST) [7, 12]. In full
macular translocation, better functional improvements have
been described in some reports, but a considerably higher
rate of RD may occur (8–26%) [1, 2, 8, 26, 28]. This
technique is also more complex and time-consuming
compared to the translocation of a free RPE-choroid graft.
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This study also had a better outcome in terms of loss of
≥2 lines and average vision compared with the Photody-
namic Therapy (TAP) Investigation and the Verteporfin in
Photodynamic Therapy (VIP) Trial, even despite the large
size (median 10 DA) of the lesions we treated with an RPE-
choroid graft [34, 36, 37].
However, one has to be careful to compare the results of
this extended pilot study to the other treatment modalities
that were studied in prospective controlled trials, whereas
all surgical approaches (except the SST studies) have been
uncontrolled single-center pilot studies.
The free RPE-choroid graft was revascularized in our
patients as revealed by the early fluorescence of the graft by
FA and the perfused parallel oriented vessels of the graft by
ICG (Fig. 4) (Maaijwee et al., unpublished data). This was
histologically confirmed in a pig model by demonstration
of bridging vessels arising from the underlying recipient
layer into the graft and not into the edge of the graft [18].
However, Maclaren et al. reported on one patient with a
graft perfused from its periphery by blood entering
horizontally through a contact point with the surrounding
macular choroid as estimated by high speed angiography
[20]. This is plausible, as in skin grafts the major
contribution to revascularization of the graft originates
from the underlying bed, and also, but less often, from the
graft margins [6, 14].
Irregular accumulation of hyperpigmentation developed
typically from 3 months after surgery onwards, at the
margins or beside the graft (in the atrophic area), and
increased with time (Fig. 4). RPE wound repair in the elderly
probably occurs by cell migration and elongation [33]. We
suggest that this hyperpigmentation at the margins of the
graft may be explained by a crowding phenomenon of the
RPE cells, because the relatively normal Bruch’s membrane
ends abruptly at the graft’s margin. The accumulation of dark
pigment in the atrophic area adjacent to the graft might be a
reaction to the membrane extraction, and may consist of
choroidal melanin as well as remnants of RPE-cells.
MacLaren et al. reported on the long-term (≥5 years)
function of a free RPE-choroid graft taken from the
paramacular area in four patients, with decline in VA in
three patients and loss of fixation in all [19]. As OCT
suggested loss of photoreceptor outer segments, as was also
observed in this study, they hypothesized that this may be
explained by chronic photoreceptor apoptosis, initiated by
either surgery or the disease process itself [19]. They also
warned against unduly optimistic expectations from studies
with a shorter follow-up. Nevertheless, several of their
findings may be interpreted positively. Firstly, fibrosis and
recurrent choroidal membranes were not a major problem,
whereas this occurs regularly after laser coagulation,
membrane extraction and macular translocation surgery.
The recurrence rate in our study was 13%, but is probably
underestimated, as angiography was only performed if
pathology was clinically suspected. Secondly, if surgical
trauma indeed causes photoreceptor damage, less surgical
damage might improve the long-term results [17]. In our
study, better photoreceptor survival might be expected, as
the free graft was taken from the midperiphery, which
reduces submacular manipulation, compared to the use of a
juxta-foveal site as described by Stanga and MacLaren et
al. [19, 32].
In fact, at this moment the main challenge is to find a
reproducible and safe way to deliver the free graft under the
macula in one go without further manipulation. We
hypothesize that, with improved instrumentation and
subsequent less trauma, the functional results may further
improve and enable us to start a controlled trial. With
promising pharmaceutical agents like anti-VEGF being
developed and available at present, RPE-choroid graft
surgery should be perfected and be available as a last-
resort option to patients not treatable or no longer
responding to approaches with less potential complications.
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